Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines to address areas of high unmet patient need. Their approach revolves around their proprietary Glyph™ technology platform, which leverages the lymphatic system to enhance the oral administration of drugs. This innovative platform overcomes limitations that have historically hindered the development of oral therapies for neuropsychiatric conditions, enabling oral bioavailability, bypassing first-pass metabolism, and reducing hepatotoxicity.

Seaport is led by an experienced team with a proven track record in neuropsychiatric drug development, including key players from PureTech Health and Karuna Therapeutics. They have assembled a diverse and accomplished board of directors, including renowned experts in the pharmaceutical industry. The company is actively advancing a pipeline of first and best-in-class medicines based on the Glyph platform, aiming to address the needs of patients suffering from depression, anxiety, and other neuropsychiatric disorders.

Seaport Therapeutics is a clinical-stage biopharmaceutical company committed to advancing novel neuropsychiatric medicines to address significant unmet needs in patients suffering from conditions like depression and anxiety. Their innovative approach leverages their proprietary Glyph technology platform, which enables oral bioavailability and overcomes limitations faced by traditional drug delivery methods. Seaport's mission is to provide first and best-in-class medicines for people living with neuropsychiatric disorders by developing drugs that are more effective, safer, and easier to administer, ultimately improving the lives of millions affected by these conditions.

Seaport Therapeutics promotes a culture of innovation and collaboration, focused on advancing novel neuropsychiatric medicines. The company is led by a team of experienced scientists, clinicians, and key opinion leaders, emphasizing a strong commitment to addressing unmet patient needs and developing first-in-class medicines. Seaport's culture values diversity and inclusion, as evidenced by the company's leadership team and board members, which reflect a broad range of expertise and backgrounds.

Seaport Therapeutics does not explicitly mention a specific diversity, equity and inclusion (DE&I) approach on its website. However, its press releases and executive team bios showcase a diverse leadership team with several women and people of color in leadership roles. This suggests an emphasis on building a diverse workforce, though a formal commitment or policy is not stated.